BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/26/2025 7:27:59 AM | Browse: 2 | Download: 11
 |
Received |
|
2025-04-02 07:35 |
|
Peer-Review Started |
|
2025-04-02 07:35 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2025-04-20 19:02 |
|
Revised |
|
2025-04-22 19:46 |
|
Second Decision |
|
2025-06-05 02:50 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2025-06-07 05:08 |
|
Articles in Press |
|
2025-06-07 05:08 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-06-16 07:26 |
|
Publish the Manuscript Online |
|
2025-06-26 07:27 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Minireviews |
| Article Title |
Hope on the horizon: Emerging therapies for hepatitis D
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Zaigham Abbas and Minaam Abbas |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Zaigham Abbas, AGAF, FACG, FACP, FRCP, Head, Professor, Department of Hepatogastroenterology, Dr. Ziauddin University Hospital Clifton, Clifton, Karachi 75600, Sindh, Pakistan. drzabbas@gmail.com |
| Key Words |
Hepatitis D; Hepatitis B; Treatment; Pegylated interferon; Bulevirtide; Nucleic acid polymers; Lonafarnib; Tobevibart; Elebsiran |
| Core Tip |
New therapeutic options for hepatitis D are emerging, offering hope for improved treatment outcomes. Pegylated interferon-alpha is currently the primary treatment for hepatitis D, but it has limitations, including significant adverse effects and low response rates. Several novel therapies are being developed. Bulevirtide, HH003, and tobevibart are entry inhibitors. Other drugs include pegylated interferon-lambda, a type III interferon; lonafarnib, a prenylation inhibitor that prevents viral replication with synergistic effects when combined with pegylated interferon-alpha; REP 2139, a nucleic acid polymer that inhibits virus entry and replication; and small interfering RNAs, including elebsiran that interfere with translation of hepatitis B virus RNA. |
| Publish Date |
2025-06-26 07:27 |
| Citation |
<p>Abbas Z, Abbas M. Hope on the horizon: Emerging therapies for hepatitis D. <i>World J Hepatol</i> 2025; 17(6): 107963</p> |
| URL |
https://www.wjgnet.com/1948-5182/full/v17/i6/107963.htm |
| DOI |
https://dx.doi.org/10.4254/wjh.v17.i6.107963 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
